Pfizer and partner BioNTech of Germany are keeping pace with the speed of the sweeping pandemic as they finish dosing in the first cohort of their COVID-19 phase 1/2 clinical trial.

It’s a small study, with just 12 participants, but all have been dosed with BioNTech’s vaccine candidate BNT162 six days after the trial started. Pfizer said it plans to run a U.S. study of BNT162 upon regulatory approval, “which is expected shortly.” Source: Fierce Biotech 29/4/2020